PhaseBio Pharmaceuticals, Inc. PHAS · Stock Open PhaseBio Pharmaceuticals, Inc. in new tab
PhaseBio Pharmaceuticals, Inc. Analysis (PHAS)
Is PhaseBio Pharmaceuticals, Inc. a good investment? PhaseBio Pharmaceuticals, Inc. (PHAS) is currently trading at 0.0701 USD.
Investor FAQ
Does PhaseBio Pharmaceuticals, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is PhaseBio Pharmaceuticals, Inc.?
PhaseBio Pharmaceuticals, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
Company Profile
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Community Discussion